Συγγραφείς:
Baliakas, P.
Mattsson, M.
Hadzidimitriou, A.
Minga, E.
Agathangelidis, A.
Sutton, L.-A.
Scarfo, L.
Davis, Z.
Yan, X.-J.
Plevova, K.
Sandberg, Y.
Vojdeman, F.J.
Tzenou, T.
Chu, C.C.
Veronese, S.
Mansouri, L.
Smedby, K.E.
Giudicelli, V.
Nguyen-Khac, F.
Panagiotidis, P.
Juliusson, G.
Anagnostopoulos, A.
Lefranc, M.-P.
Trentin, L.
Catherwood, M.
Montillo, M.
Niemann, C.U.
Langerak, A.W.
Pospisilova, S.
Stavroyianni, N.
Chiorazzi, N.
Oscier, D.
Jelinek, D.F.
Shanafelt, T.
Darzentas, N.
Belessi, C.
Davi, F.
Ghia, P.
Rosenquist, R.
Stamatopoulos, K.
Λέξεις-κλειδιά:
cyclophosphamide; fludarabine; rituximab, adult; aged; cancer chemotherapy; cancer immunotherapy; chronic lymphatic leukemia; female; follow up; gene deletion; gene expression; gene mutation; human; immunogenetics; Letter; long term survival; major clinical study; male; retrospective study; chronic lymphatic leukemia; drug therapy; immunotherapy; middle aged; mortality; survival rate; very elderly; young adult, Adult; Aged; Aged, 80 and over; Drug Therapy; Female; Humans; Immunotherapy; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Retrospective Studies; Survival Rate; Young Adult
